Clinical Trials /

Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133

NCT02541370

Description:

RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells. PURPOSE: This clinical trial is studying genetically engineered lymphocyte therapy in treating patients with Relapsed and/or Chemotherapy Refractory Advanced Malignancies.

Related Conditions:
  • Acute Leukemia
  • Breast Carcinoma
  • Colorectal Carcinoma
  • Hepatocellular Carcinoma
  • Malignant Brain Neoplasm
  • Ovarian Carcinoma
  • Pancreatic Carcinoma
Recruiting Status:

Unknown status

Phase:

Phase 1

Trial Eligibility

Document

Title

  • Brief Title: Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133
  • Official Title: Clinical Study of Chimeric CD(Cluster of Differentiation)133 Antigen Receptor-modified T Cells in Relapsed and/or Chemotherapy Refractory Malignancies

Clinical Trial IDs

  • ORG STUDY ID: s2015-080-03
  • NCT ID: NCT02541370

Conditions

  • Liver Cancer
  • Pancreatic Cancer
  • Brain Tumor
  • Breast Cancer
  • Ovarian Tumor
  • Colorectal Cancer
  • Acute Myeloid and Lymphoid Leukemias

Interventions

DrugSynonymsArms

Purpose

RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells.

PURPOSE: This clinical trial is studying genetically engineered lymphocyte therapy in treating patients with Relapsed and/or Chemotherapy Refractory Advanced Malignancies.

Detailed Description

I. Determine the safety and feasibility of the chimeric antigen receptor T cells transduced with the anti-CD133 (cluster of differentiation antigen 133 ) vector (referred to as CART-133 cells).

II. Determine duration of in vivo survival of CART-133 cells. RT-PCR (reverse transcription polymerase chain reaction) analysis of whole blood will be used to detect and quantify survival of CART-133 TCR (T-cell receptor) zeta:CD137 and TCR zeta cells over time.

SECONDARY OBJECTIVES:

I. For patients with detectable disease, measure anti-tumor response due to CART-133 cell infusions.

II. To determine if the CD137 transgene is superior to the TCR zeta only transgene as measured by the relative engraftment levels of CART-133 TCR zeta:CD137 and TCR zeta cells over time.

III. Estimate relative trafficking of CART-133 cells to tumor in bone marrow and lymph nodes.

IV. For patients with stored or accessible tumor cells determine tumor cell killing by CART-133 cells in vitro.

V. Determine if cellular or humoral host immunity develops against the murine anti-CD133, and assess correlation with loss of detectable CART-133 (loss of engraftment).

VI. Determine the relative subsets of CART-133 T cells (Tcm, Tem, and Treg).

Trial Arms

NameTypeDescriptionInterventions
anti-CD133 CAR T cellsExperimentalDose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation. Patients receive anti-CD133-CAR retroviral vector-transduced autologous-derived T cells on days 0, 1, 2 in the absence of disease progression or unacceptable toxicity.

    Eligibility Criteria

    Inclusion Criteria:

    1. Chemotherapy refractory or relapsed CD133-positive liver cancer, pancreatic cancer, brain tumor ,breast cancer, ovarian tumors, colorectal cancer and acute leukemia.

    2. Patients must be 18 years of age or older.

    3. Patients must have an ECOG (Eastern Cooperative Oncology Group )performance status of 0-2.

    4. Patients must have evidence of adequate bone marrow reserve, hepatic and renal function as evidenced by the following laboratory parameters:

    Absolute neutrophil count greater than 1500/mm3. Platelet count greater than 100,000/mm3. Hemoglobin greater than 10g/dl (patients may receive transfusions to meet this parameter).

    Total bilirubin < 1.5 times upper limits of normal. Serum creatinine less than or equal to 1.6 mg/ml or the creatinine clearance must be greater than 70 ml/min/1.73m.

    5. Seronegative for HIV antibody.

    6. Seronegative for active hepatitis B, and seronegative for hepatitis C antibody.

    7. Patients must be willing to practice birth control during and for four months following treatment. NOTE: women of child-bearing age must have evidence of negative pregnancy test.

    8. Patients must be willing to sign an informed consent.

    Exclusion Criteria:

    - 1. Patients with life expectancy less than 12 months will be excluded. 2. Patients with uncontrolled hypertension (> 160/95), unstable coronary disease evidenced by uncontrolled arrhythmias, unstable angina, decompensated congestive heart failure (> New York Heart Association Class II), or myocardial infarction within 6 months of study will be excluded.

    3. Patients with any of the following pulmonary function abnormalities will be excluded: FEV(forced expiratory volume), < 30% predicted; DLCO (diffusing capacity of lung for carbon monoxide) < 30% predicted (post-bronchodilator); Oxygen Saturation less than 90% on room air.

    4. Patients with severe liver and kidney dysfunction or consciousness disorders will be excluded.

    5. Pregnant and/or lactating women will be excluded. 6. Patients with active infections, including HIV, will be excluded, due to unknown effects of the vaccine on lymphoid precursors.

    7. Patients with any type of primary immunodeficiencies will be excluded from the study.

    8. Patients requiring corticosteroids (other than inhaled) will be excluded. 9. Patients with history of T cell tumors will be excluded. 10. Patients who are participating or participated any other clinical trials in latest 30 days will be excluded.

    11. Patients with relapsed acute leukemia after allogeneic stem cell transplantation

    Maximum Eligible Age:70 Years
    Minimum Eligible Age:18 Years
    Eligible Gender:All
    Healthy Volunteers:No

    Primary Outcome Measures

    Measure:Occurrence of study related adverse events
    Time Frame:Until week 24
    Safety Issue:
    Description:defined as >= Grade 3 signs/symptoms, laboratory toxicities, and clinical

    Secondary Outcome Measures

    Measure:Anti-tumor responses to CART-133 cell infusions
    Time Frame:up to 24 weeks
    Safety Issue:
    Description:

    Details

    Phase:Phase 1
    Primary Purpose:Interventional
    Overall Status:Recruiting
    Lead Sponsor:Chinese PLA General Hospital

    Trial Keywords

      Last Updated

      September 2, 2015